Financial Results March 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shree Ganesh Remedies' board approved audited FY25 results on May 19, 2025, with statutory auditor Chaudhary Shah & Associates LLP issuing an unmodified (clean) opinion on both standalone and consolidated results. Standalone revenue from operations fell to Rs 10,859.65 lakh from Rs 12,589.54 lakh in FY24, a decline of about 13.7%, while total income came in at Rs 11,232.60 lakh. Profit before tax rose to Rs 2,309.31 lakh from Rs 2,115.15 lakh, but profit after tax dropped to Rs 1,629.21 lakh from Rs 2,111.40 lakh due to higher tax outgo, dragging basic EPS down to Rs 10.01 from Rs 17.96. Despite the top-line fall, operating profitability strengthened, with EBITDA margin expanding roughly to the low-30s% range on the back of lower material and other expenses. The board also appointed M/s Prachi Bansal & Associates as Secretarial Auditors for FY25 and a five-year term through FY30, and re-appointed M/s SNDK & Associates LLP as Internal Auditors for FY26.
A clean audit opinion and healthy EBITDA margin expansion are positives for shareholders, but the double-digit fall in revenue and PAT along with EPS almost halving year-on-year may weigh on near-term sentiment. Investors should watch for sustainability of the margin improvement and any recovery in topline in FY26.